LQLiujia Qian

Liujia Qian

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Liujia Qian has a total of 153 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The 2025 Westlake Autumn Symposium for Al Proteomics and Virtual Cell

    by Rui Sun, Ruedi Aebersold, Qi Xiao, Matthias Mann, Yan Zhou, Albert J R Heck, Yingrui Wang, Uwe Völker, Xue Cai, Charles Boone, et al.


  • Open Access

    Multi-organ Proteomic Landscape of COVID-19 Autopsies

    by Xiu Nie, Liujia Qian, Rui Sun, Bo Huang, Xiaochuan Dong, Qi Xiao, Qiushi Zhang, Tian Lu, Liang Yue, Shuo Chen, et al.

    The molecular pathology of multi-organ injuries in COVID-19 patients remains unclear, preventing effective therapeutics development. Here, we report an in-depth multi-organ proteomic landscape of COVID-19 patient autopsy samples. By integrative analysis of proteomes of seven organs, namely lung, spleen, liver, heart, kidney, thyroid and testis, we characterized 11,394 proteins, in which 5336 were perturbed in COVID-19 patients compared to controls. Our data showed that CTSL, rather than ACE2, was significantly upregulated in the lung from COVID-19 patients. Dysregulation of protein translation, glucose metabolism, fatty acid metabolism was detected in multiple organs. Our data suggested upon SARS-CoV-2 infection, hyperinflammation might be triggered which in turn induces damage of gas exchange barrier in the lung, leading to hypoxia, angiogenesis, coagulation and fibrosis in the lung, kidney, spleen, liver, heart and thyroid. Evidence for testicular injuries included reduced Leydig cells, suppressed cholesterol biosynthesis and sperm mobility. In summary, this study depicts the multi-organ proteomic landscape of COVID-19 autopsies, and uncovered dysregulated proteins and biological processes, offering novel therapeutic clues. HIGHLIGHTS: Characterization of 5336 regulated proteins out of 11,394 quantified proteins in the lung, spleen, liver, kidney, heart, thyroid and testis autopsies from 19 patients died from COVID-19. CTSL, rather than ACE2, was significantly upregulated in the lung from COVID-19 patients. Evidence for suppression of glucose metabolism in the spleen, liver and kidney; suppression of fatty acid metabolism in the kidney; enhanced fatty acid metabolism in the lung, spleen, liver, heart and thyroid from COVID-19 patients; enhanced protein translation initiation in the lung, liver, renal medulla and thyroid. Tentative model for multi-organ injuries in patients died from COVID-19: SARS-CoV-2 infection triggers hyperinflammatory which in turn induces damage of gas exchange barrier in the lung, leading to hypoxia, angiogenesis, coagulation and fibrosis in the lung, kidney, spleen, liver, heart, kidney and thyroid. Testicular injuries in COVID-19 patients included reduced Leydig cells, suppressed cholesterol biosynthesis and sperm mobility.

  • Top Cited Papers

    Proteomic and Metabolomic Characterization of COVID-19 Patient Sera

    by Bo Shen, Xiao Yi, Yaoting Sun, Xiaojie Bi, Juping Du, Chao Zhang, Sheng Quan, Fangfei Zhang, Rui Sun, Liujia Qian, et al.


  • Open Access

    Proteomics Uncovers Immunosuppression in COVID-19 Patients with Long Disease Course

    by Shaohua Tang, Rui Sun, Qi Xiao, Tingting Mao, Weigang Ge, Chongquan Huang, Meng Luo, Liujia Qian, Hao Chen, Qiushi Zhang, et al.

    Little is known regarding why a subset of COVID-19 patients exhibited prolonged positivity of SARS-CoV-2 infection. Here, we studied the sera proteomic dynamics in 37 COVID-19 patients over nine weeks, quantifying 2700 proteins with high quality. Remarkably, we found that during the first three weeks since disease onset, while clinical symptoms and outcome were indistinguishable, patients with prolonged disease course displayed characteristic immunological responses including enhanced Natural Killer cell-mediated innate immunity and regulatory T cell-mediated immunosuppression. We further showed that it is possible to predict the length of disease course using machine learning based on blood protein levels during the first three weeks. Validation in an independent cohort achieved an accuracy of 82%. In summary, this study presents a rich serum proteomic resource to understand host responses in COVID-19 patients and identifies characteristic Treg-mediated immunosuppression in patients with prolonged disease course, nominating new therapeutic target and diagnosis strategy.


  • Open Access

    Proteomic and Metabolomic Characterization of COVID-19 Patient Sera

    by Bo Shen, Xiao Yi, Yaoting Sun, Xiaojie Bi, Juping Du, Chao Zhang, Sheng Quan, Fangfei Zhang, Rui Sun, Liujia Qian, et al.

    SUMMARY: Severe COVID-19 patients account for most of the mortality of this disease. Early detection and effective treatment of severe patients remain major challenges. Here, we performed proteomic and metabolomic profiling of sera from 46 COVID-19 and 53 control individuals. We then trained a machine learning model using proteomic and metabolomic measurements from a training cohort of 18 non-severe and 13 severe patients. The model correctly classified severe patients with an accuracy of 93.5%, and was further validated using ten independent patients, seven of which were correctly classified. We identified molecular changes in the sera of COVID-19 patients implicating dysregulation of macrophage, platelet degranulation and complement system pathways, and massive metabolic suppression. This study shows that it is possible to predict progression to severe COVID-19 disease using serum protein and metabolite biomarkers. Our data also uncovered molecular pathophysiology of COVID-19 with potential for developing anti-viral therapies.